Lijin Biopharmaceutical Technology

Lijin Biopharma is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to developing innovative antibody-based therapies for cancer. The company was founded by Dr. Jin Li, a prominent figure in the Chinese biotech industry and co-founder of Henlius, with a focus on next-generation bispecific antibodies and T-cell engagers. Lijin's proprietary technology platform is designed to create multi-specific biologics that enhance anti-tumor activity while minimizing systemic toxicity. Its lead program, LJ001, is a bispecific antibody targeting Claudin 18.2 and CD3, currently in Phase 1 clinical trials for the treatment of advanced gastric and pancreatic cancers. Beyond its lead asset, the company is advancing a pipeline of candidates targeting GPC3, HER2, and other validated tumor antigens. Lijin Biopharma aims to address the limitations of current immunotherapies through precision engineering and strategic clinical development.